Nuvation Bio Balance Sheet Health
Financial Health criteria checks 5/6
Nuvation Bio has a total shareholder equity of $502.7M and total debt of $8.4M, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are $571.6M and $68.9M respectively.
Key information
1.7%
Debt to equity ratio
US$8.43m
Debt
| Interest coverage ratio | n/a |
| Cash | US$549.14m |
| Equity | US$502.71m |
| Total liabilities | US$68.87m |
| Total assets | US$571.58m |
Recent financial health updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20
Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Recent updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Financial Position Analysis
Short Term Liabilities: NUVB's short term assets ($565.0M) exceed its short term liabilities ($59.0M).
Long Term Liabilities: NUVB's short term assets ($565.0M) exceed its long term liabilities ($9.8M).
Debt to Equity History and Analysis
Debt Level: NUVB has more cash than its total debt.
Reducing Debt: NUVB's debt to equity ratio has increased from 0.2% to 1.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NUVB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NUVB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.8% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvation Bio Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |